avutometinib (VS-6766)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Roche, Verastem

Drug class:

MEK inhibitor, BRAF inhibitor, cRAF inhibitor

Related drugs:

›

KRAS wild-type	Ovarian Cancer	KRAS wild-type	Ovarian Cancer	VS-6766 + VS-6063 Sensitive: B - Late Trials VS-6766 + VS-6063 Sensitive : B	VS-6766 + VS-6063 Sensitive: B - Late Trials VS-6766 + VS-6063 Sensitive : B
KRAS G12V	Ovarian Serous Adenocarcinoma	KRAS G12V	Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
BRAF mutation	Ovarian Cancer	BRAF mutation	Ovarian Cancer	VS-6766 Sensitive: C2 – Inclusion Criteria VS-6766 Sensitive : C2	VS-6766 Sensitive: C2 – Inclusion Criteria VS-6766 Sensitive : C2
KRAS mutation	Ovarian Cancer	KRAS mutation	Ovarian Cancer	VS-6766 Sensitive: C2 – Inclusion Criteria VS-6766 Sensitive : C2	VS-6766 Sensitive: C2 – Inclusion Criteria VS-6766 Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	VS-6766 Sensitive: C2 – Inclusion Criteria VS-6766 Sensitive : C2	VS-6766 Sensitive: C2 – Inclusion Criteria VS-6766 Sensitive : C2
KRAS mutation	Ovarian Cancer	KRAS mutation	Ovarian Cancer	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
KRAS G12V	Ovarian Cancer	KRAS G12V	Ovarian Cancer	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
KRAS G12D	Ovarian Serous Adenocarcinoma	KRAS G12D	Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3
KRAS G12A	Ovarian Serous Adenocarcinoma	KRAS G12A	Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3
KRAS mutation	Endometrial Cancer	KRAS mutation	Endometrial Cancer	VS-6766 Sensitive: C3 – Early Trials VS-6766 Sensitive : C3	VS-6766 Sensitive: C3 – Early Trials VS-6766 Sensitive : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	VS-6766 Sensitive: C3 – Early Trials VS-6766 Sensitive : C3	VS-6766 Sensitive: C3 – Early Trials VS-6766 Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + VS-6766 Sensitive: C3 – Early Trials sotorasib + VS-6766 Sensitive : C3	sotorasib + VS-6766 Sensitive: C3 – Early Trials sotorasib + VS-6766 Sensitive : C3
KRAS G13A	Non Small Cell Lung Cancer	KRAS G13A	Non Small Cell Lung Cancer	everolimus + VS-6766 Sensitive: C3 – Early Trials everolimus + VS-6766 Sensitive : C3	everolimus + VS-6766 Sensitive: C3 – Early Trials everolimus + VS-6766 Sensitive : C3
KRAS G13A	Non Small Cell Lung Cancer	KRAS G13A	Non Small Cell Lung Cancer	VS-6766 Sensitive: C3 – Early Trials VS-6766 Sensitive : C3	VS-6766 Sensitive: C3 – Early Trials VS-6766 Sensitive : C3
KRAS G12A	Non Small Cell Lung Cancer	KRAS G12A	Non Small Cell Lung Cancer	VS-6766 Sensitive: C3 – Early Trials VS-6766 Sensitive : C3	VS-6766 Sensitive: C3 – Early Trials VS-6766 Sensitive : C3
AXL overexpression	Ovarian Cancer	AXL overexpression	Ovarian Cancer	VS-6766 + BGB324 Sensitive: D – Preclinical VS-6766 + BGB324 Sensitive : D	VS-6766 + BGB324 Sensitive: D – Preclinical VS-6766 + BGB324 Sensitive : D
KRAS mutation	Ovarian Cancer	KRAS mutation	Ovarian Cancer	VS-6766 + BGB324 Sensitive: D – Preclinical VS-6766 + BGB324 Sensitive : D	VS-6766 + BGB324 Sensitive: D – Preclinical VS-6766 + BGB324 Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + adagrasib + VS-6766 Sensitive: D – Preclinical sotorasib + adagrasib + VS-6766 Sensitive : D	sotorasib + adagrasib + VS-6766 Sensitive: D – Preclinical sotorasib + adagrasib + VS-6766 Sensitive : D
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	sotorasib + adagrasib + VS-6766 Sensitive: D – Preclinical sotorasib + adagrasib + VS-6766 Sensitive : D	sotorasib + adagrasib + VS-6766 Sensitive: D – Preclinical sotorasib + adagrasib + VS-6766 Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + VS-6766 + VS-6063 Sensitive: D – Preclinical sotorasib + VS-6766 + VS-6063 Sensitive : D	sotorasib + VS-6766 + VS-6063 Sensitive: D – Preclinical sotorasib + VS-6766 + VS-6063 Sensitive : D
KRAS G12D + KRAS G12V	Pancreatic Cancer	KRAS G12D + KRAS G12V	Pancreatic Cancer	repotrectinib + VS-6766 Sensitive: D – Preclinical repotrectinib + VS-6766 Sensitive : D	repotrectinib + VS-6766 Sensitive: D – Preclinical repotrectinib + VS-6766 Sensitive : D
KRAS wild-type	Ovarian Serous Adenocarcinoma	KRAS wild-type	Ovarian Serous Adenocarcinoma	VS-6766 + VS-4718 Sensitive: D – Preclinical VS-6766 + VS-4718 Sensitive : D	VS-6766 + VS-4718 Sensitive: D – Preclinical VS-6766 + VS-4718 Sensitive : D
RAF1 V207G	Ovarian Serous Adenocarcinoma	RAF1 V207G	Ovarian Serous Adenocarcinoma	VS-6766 + VS-4718 Sensitive: D – Preclinical VS-6766 + VS-4718 Sensitive : D	VS-6766 + VS-4718 Sensitive: D – Preclinical VS-6766 + VS-4718 Sensitive : D
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	panitumumab + VS-6766 Sensitive: D – Preclinical panitumumab + VS-6766 Sensitive : D	panitumumab + VS-6766 Sensitive: D – Preclinical panitumumab + VS-6766 Sensitive : D
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	VS-6766 Sensitive: D – Preclinical VS-6766 Sensitive : D	VS-6766 Sensitive: D – Preclinical VS-6766 Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	VS-6766 Sensitive: D – Preclinical VS-6766 Sensitive : D	VS-6766 Sensitive: D – Preclinical VS-6766 Sensitive : D

avutometinib (VS-6766)

Associations
(27)

Associations
(27)

avutometinib (VS-6766)

Associations(27)

Associations(27)

Associations
(27)

Associations
(27)